反应详情

The title compound was prepared analogously to Example A(97) where 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1H-imidazole-5-carbaldehyde and 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopentanecarbonitrile (Example A(189) (was substituted in place of 2-{4-[2-(2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl}-2-methylpropanenitrile. 1H NMR (400 MHz, CDCl3) δ: 1.35–2.16 (m, 16 H), 2.42–2.82 (m, 7 H), 3.33 (s, 3 H), 3.74 (d, J=16 Hz, 1 H), 3.84 (d, J=16 Hz, 1 H), 7.14–7.19 (m, 2 H), 7.36–7.41 (m, 1 H), 8.71 (s, 1 H), 9 (s, 1 H), 10.9 (s, 1 H). Anal. Calcd. For C31H34FN5O3.0.75H2O: C, 66.83; H, 6.42; N, 12.57. Found: C, 66.93; H, 6.18; N, 12.45. MS (ESI): 544 (M+H)+.